Impact Factor
2.88
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.08
125 total citations
h5-index
14
h5 depth signal
Cited share
67.7%
44 of 65
Total citations
125
Citation footprint
Metric signal
2.50
External metric anchor
Self-citation
3.2%
4 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
149
China
57
Canada
31
Spain
27
United Kingdom
20
Citing Fields of Research
Genetics & Genomics
158
Pharmacology & Toxicology
121
Cardiology
44
Hematology
31
Allergies
30
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,614
Articles tracked across the journal lifetime
Indexed publication set
65
44 cited publications
Last 12 months
43
3.6 publications/month
Open access share
18.6%
8 OA publications in the last year
Leading citing country
United States
149 citing publications
Leading citing field
Genetics & Genomics
158 citing publications
Latest tracked publication
7 October 2026
10 recent records available
Coverage & Indexing History
v15n1, Jan. 2005-
v15n1, Jan. 2005-
Research Focus & Classification
Indexed Subjects
Genetics & Genomics
Pharmacology & Toxicology
Cardiology
Hematology
Anesthetic & Pain Medicine
Mycobacterial Diseases
Broad Categories
Genetics, Medical
Pharmacology
Pharmacology & Toxicology
Cardiology
Genetics & Genomics
Allergies
Transplantation
Substance Abuse
MeSH Descriptors
Genomics
Pharmacogenetics
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/fpc.0000000000000623
Open DOI
Distribution of the J1 haplotype variant rs2267439 across CYP2D6 diplotypes and its impact on risperidone metabolism
CYP2D6 is a highly polymorphic pharmacogene responsible for the metabolism of more than 20% of commonly prescribed drugs. Clinical implementation of CYP2D6 pharmacogenetics relies on star allele nomenclature and the Activity Score system...
02
DOI 10.1097/fpc.0000000000000624
Open DOI
Pharmacogenetics of inhaled corticosteroids in obesity-related childhood asthma
Asthma is a multifactorial disease driven by genetic and environmental factors that influence pathogenesis and therapeutic response. Obesity and asthma share overlapping inflammatory pathways that worsen disease severity and impair medic...
03
DOI 10.1097/fpc.0000000000000614
Open DOI
Individualized perampanel response and efficacy in patients with refractory epilepsy: the need for ATP-binding cassette B1 genotyping and therapeutic drug monitoring to work in tandem
Objective: This study analyzed the correlation and differences between the gene polymorphisms of ATP-binding cassette B1 ( ABCB1 ), which encode the efflux drug transporter P-glycoprotein, and the efficacy and plasma concentration of per...
04
DOI 10.1097/fpc.0000000000000621
Open DOI
Beyond enrichment: pharmacogenetic heterogeneity in treatment-resistant depression
Objectives: Genetic variation has been proposed as a potential contributor to antidepressant nonresponse, but its role in treatment-resistant depression (TRD) remains unclear. This study used pharmacogenetics (PGx) to characterize geneti...
05
DOI 10.1097/fpc.0000000000000622
Open DOI
Genetic variation in SLCO1B1 is associated with methotrexate intolerance symptoms in juvenile idiopathic arthritis patients
Methotrexate (MTX) treatment of juvenile idiopathic arthritis (JIA) is complicated by severe intolerance in approximately 30% of patients. MTX intolerance typically presents as nausea (anticipatory and postdose), vomiting, and behavioral...
06
DOI 10.1097/fpc.0000000000000618
Open DOI
Clinical outcomes stratified by CYP2C19 phenotypes in intracranial artery stenting patients with genotype-guided antiplatelet regimens: a real-world single-center retrospective cohort study
Objectives: Clinical trial evidence is scarce for optimal antiplatelet strategies in patients undergoing intracranial artery stenting with CYP2C19 loss‑of‑function alleles, especially regarding the efficacy‑safety balance. Methods: This ...
07
DOI 10.1097/fpc.0000000000000620
Open DOI
Haplotype-based association of HTR2A rs6311–rs6313 with early risperidone–clozapine response in Batak patients with schizophrenia
Background: Risperidone–clozapine response varies substantially in schizophrenia. HTR2A polymorphisms may influence antipsychotic response, but rs6311–rs6313 haplotypes remain unexplored in the Indonesian Batak population. This study eva...
08
DOI 10.1097/fpc.0000000000000616
Open DOI
Prevalence and clinical impact of the uncommon DPYD c.257C>T (Pro86Leu) variant in a multiethnic cohort receiving fluoropyrimidine therapy
Pre-emptive genotyping and genotype-guided dose adjustments are generally recommended for seven hypofunctional polymorphisms in the DPYD gene that are associated with fluoropyrimidine toxicity. However, targeted genotyping may miss uncom...
09
DOI 10.1097/fpc.0000000000000613
Open DOI
Association of UGT and CYP genotype-predicted activity with tyrosine kinase inhibitor toxicity
Associations between genetically predicted activity of metabolic enzymes and risks of adverse events from tyrosine kinase inhibitors (TKIs) may inform dosing to optimize treatment outcomes in patients with cancer. The goal of this study ...
10
DOI 10.1097/fpc.0000000000000600
Open DOI
The HTR2A rs6311 and rs6313 polymorphisms and atypical antipsychotics response in schizophrenia: a scoping review
The HTR2A polymorphisms rs6311 (A−1438G) and rs6313 (T102C) have been thoroughly studied for their impact on atypical antipsychotics (AAPs) responsiveness in schizophrenia. However, the results remain inconsistent owing to the complex ge...
Bibliographical & Catalog Notes
Title from cover.
Latest issue consulted: Vol. 15, no. 3 (Mar. 2005).
Also available online.